About Encellin
Encellin is a company based in San Francisco (United States) founded in 2015 by Crystal Nyitray. Encellin has raised $18.45 million across 4 funding rounds from investors including Khosla Ventures, Y Combinator and SV Latam Capital. Encellin offers products and services including ENCRT. Encellin operates in a competitive market with competitors including Organogenesis, Sofregen, BioTissue, Reapplix and Acera Surgical, among others.
- Headquarter San Francisco, United States
- Founders Crystal Nyitray
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.45 M (USD)
in 4 rounds
-
Latest Funding Round
$9.94 M (USD), Series A
Sep 20, 2023
-
Investors
Khosla Ventures
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Encellin
Encellin offers a comprehensive portfolio of products and services, including ENCRT.
Implant that encapsulates cells to deliver therapeutics for chronic diseases.
People of Encellin
Unlock access to complete
Unlock access to complete
Funding Insights of Encellin
Encellin has successfully raised a total of $18.45M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $9.94 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Encellin
Encellin has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Y Combinator and SV Latam Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in science and technology startups
|
Locked | Locked | Locked |
Investor details for Encellin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Encellin
Investment portfolio details for Encellin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Encellin
Detailed financials for Encellin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Encellin Comparisons
Peer comparison for Encellin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Encellin
Encellin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Organogenesis, Sofregen, BioTissue, Reapplix and Acera Surgical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Silk-derived biomaterials are developed for soft tissue repair in surgery.
|
|
| Locked | Locked | Locked |
Regenerative biologic therapies for eye care are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of patch system for wound healing
|
|
| Locked | Locked | Locked |
Synthetic electrospun scaffolds are provided for regenerative medical uses.
|
Detailed competitors of Encellin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Encellin
Complete news archive for Encellin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Encellin
Encellin was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Encellin is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Crystal Nyitray is the current CEO of Encellin. They have also founded this company.
Encellin is a funded company, having raised a total of $18.45M across 4 funding rounds to date.
Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases.
Encellin's top competitors include Organogenesis, GeniPhys and Acera Surgical.
Encellin offers ENCRT.
Encellin has 4 investors. Key investors include Khosla Ventures, Y Combinator, SV Latam Capital, and Sand Hill Angels.